---
title: "Dementia Evaluation"
description: "Clinical decision support for comprehensive dementia workup and management"
version: "1.0"
setting: "ED, HOSP, OPD"
status: draft
tags:
  - cognitive
  - dementia
  - alzheimer
  - outpatient
---

<div class="draft-warning-banner">
  <div class="icon">⚠️</div>
  <div class="content">
    <div class="title">DRAFT - Pending Review</div>
    <div class="description">This plan requires physician review before clinical use.</div>
  </div>
</div>

# Dementia Evaluation

**DIAGNOSIS:** Dementia Evaluation
**ICD-10:** G31.9 (Degenerative disease of nervous system, unspecified); R41.81 (Age-related cognitive decline); F03.90 (Unspecified dementia without behavioral disturbance)
**SCOPE:** Comprehensive evaluation for cognitive impairment, identification of reversible causes, dementia subtype diagnosis, and symptomatic management. Covers Alzheimer's disease, vascular dementia, frontotemporal dementia, and dementia with Lewy bodies.

**STATUS:** Draft - Pending Review

---

**PRIORITY KEY:** STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting

---

## SECTION A: ACTION ITEMS

---

## 1. LABORATORY WORKUP

### 1A. Essential/Core Labs (Reversible Causes Screen)

| Test | Rationale | Target Finding | ED | HOSP | OPD | ICU |
|------|-----------|----------------|:--:|:----:|:---:|:---:|
| CBC with differential | Infection, anemia, malignancy contributing to cognitive changes | Normal | STAT | STAT | ROUTINE | - |
| BMP | Hyponatremia, uremia, hypercalcemia as causes | Normal electrolytes, BUN, Cr | STAT | STAT | ROUTINE | - |
| TSH | Hypothyroidism is reversible cause of cognitive impairment | 0.4-4.0 mIU/L | URGENT | ROUTINE | ROUTINE | - |
| Vitamin B12 | Deficiency causes reversible dementia | >300 pg/mL (>400 optimal) | URGENT | ROUTINE | ROUTINE | - |
| Folate | Deficiency contributes to cognitive impairment | >3 ng/mL | - | ROUTINE | ROUTINE | - |
| Glucose (fasting) | Diabetes management affects cognition | 70-100 mg/dL | STAT | ROUTINE | ROUTINE | - |
| Hepatic panel (LFTs, albumin) | Hepatic encephalopathy; nutritional status | Normal | - | ROUTINE | ROUTINE | - |
| Urinalysis | UTI common cause of acute confusion in elderly | Negative for infection | STAT | STAT | ROUTINE | - |

### 1B. Extended Workup (Second-line)

| Test | Rationale | Target Finding | ED | HOSP | OPD | ICU |
|------|-----------|----------------|:--:|:----:|:---:|:---:|
| Vitamin D, 25-hydroxy | Deficiency associated with cognitive decline | >30 ng/mL | - | ROUTINE | ROUTINE | - |
| Hemoglobin A1c | Chronic glucose control affects cognition | <7% | - | ROUTINE | ROUTINE | - |
| Lipid panel | Vascular risk factor for vascular dementia | LDL <100 mg/dL | - | ROUTINE | ROUTINE | - |
| Homocysteine | Elevated levels associated with AD and vascular dementia | <15 μmol/L | - | ROUTINE | ROUTINE | - |
| RPR or VDRL | Neurosyphilis (rare but treatable) | Nonreactive | - | ROUTINE | ROUTINE | - |
| HIV testing | HIV-associated neurocognitive disorder | Negative | - | ROUTINE | ROUTINE | - |
| ESR, CRP | Inflammatory/autoimmune causes | Normal | - | ROUTINE | ROUTINE | - |

### 1C. Rare/Specialized (Refractory or Atypical)

| Test | Rationale | Target Finding | ED | HOSP | OPD | ICU |
|------|-----------|----------------|:--:|:----:|:---:|:---:|
| Heavy metal panel (lead, mercury, arsenic) | Toxic exposure history | Normal | - | - | EXT | - |
| Copper, ceruloplasmin | Wilson's disease if age <50 | Normal | - | EXT | EXT | - |
| Paraneoplastic antibody panel | Autoimmune dementia; occult malignancy | Negative | - | EXT | EXT | - |
| Anti-neuronal antibodies (NMDA-R, LGI1, CASPR2, GABA-B, AMPA-R) | Autoimmune encephalitis | Negative | - | EXT | EXT | - |
| Genetic testing (APOE, PSEN1, PSEN2, APP) | Family history early-onset AD; prognostic | Variable | - | - | EXT | - |
| Prion protein gene testing | Suspected CJD with family history | No mutation | - | - | EXT | - |

---

## 2. DIAGNOSTIC IMAGING & STUDIES

### 2A. Essential/First-line

| Study | Timing | Target Finding | Contraindications | ED | HOSP | OPD | ICU |
|-------|--------|----------------|-------------------|:--:|:----:|:---:|:---:|
| MRI Brain without contrast | At initial evaluation | Assess atrophy pattern; rule out structural causes (tumor, SDH, NPH) | MRI-incompatible devices | URGENT | ROUTINE | ROUTINE | - |
| CT Head non-contrast | If MRI unavailable or contraindicated | Rule out mass, hemorrhage, hydrocephalus | None | STAT | STAT | ROUTINE | - |

### 2B. Extended

| Study | Timing | Target Finding | Contraindications | ED | HOSP | OPD | ICU |
|-------|--------|----------------|-------------------|:--:|:----:|:---:|:---:|
| MRI Brain volumetrics | Disease monitoring; clinical trials | Hippocampal and whole brain atrophy quantification | MRI contraindications | - | - | ROUTINE | - |
| FDG-PET Brain | Differentiate AD from FTD; atypical presentations | AD: temporoparietal hypometabolism; FTD: frontal/temporal hypometabolism | None | - | - | ROUTINE | - |
| Amyloid PET (florbetapir, florbetaben, flutemetamol) | Atypical age/presentation; clinical trial eligibility | Positive: amyloid deposition; negative rules out AD | None | - | - | EXT | - |
| Tau PET (flortaucipir) | Research; staging AD pathology | Pattern correlates with clinical phenotype | None | - | - | EXT | - |
| DaTscan (ioflupane I-123) | Differentiate DLB from AD | Reduced: DLB/PDD; Normal: AD | Iodine hypersensitivity | - | - | ROUTINE | - |
| EEG | Encephalopathy; CJD; seizures | AD: mild slowing; CJD: periodic sharp wave complexes | None | URGENT | ROUTINE | ROUTINE | - |
| Sleep study (polysomnography) | Sleep apnea contributing to cognition; RBD suggesting DLB | Assess AHI; REM without atonia | None | - | - | ROUTINE | - |

### 2C. Rare/Specialized

| Study | Timing | Target Finding | Contraindications | ED | HOSP | OPD | ICU |
|-------|--------|----------------|-------------------|:--:|:----:|:---:|:---:|
| SPECT (perfusion) | Alternative to PET if unavailable | Regional hypoperfusion patterns | None | - | - | EXT | - |
| MRI with SWI/GRE sequences | Cerebral amyloid angiopathy; microbleeds | Lobar microbleeds pattern | MRI contraindications | - | ROUTINE | ROUTINE | - |
| Whole body PET-CT | Paraneoplastic workup | Identify occult malignancy | None | - | EXT | EXT | - |

---

### LUMBAR PUNCTURE

**Indication:** Rapid progression, early-onset (<65), atypical presentation, suspected autoimmune or infectious etiology, clinical trial eligibility
**Timing:** ROUTINE for diagnosis clarification; URGENT if autoimmune/infectious suspected
**Volume Required:** 10-15 mL (standard diagnostic); additional for research biomarkers

| Study | Rationale | Target Finding | ED | HOSP | OPD | ICU |
|-------|-----------|----------------|:--:|:----:|:---:|:---:|
| Cell count, protein, glucose | Rule out infection, inflammation | WBC <5, protein <45 mg/dL, glucose >60% serum | URGENT | ROUTINE | ROUTINE | - |
| CSF Aβ42 (amyloid beta 1-42) | Low in Alzheimer's disease | <600 pg/mL suggests AD | - | ROUTINE | ROUTINE | - |
| CSF total tau | Elevated in neurodegeneration | <400 pg/mL normal; elevated in AD | - | ROUTINE | ROUTINE | - |
| CSF p-tau (phosphorylated tau 181) | Specific for AD pathology | Elevated in AD; Aβ42/p-tau ratio most predictive | - | ROUTINE | ROUTINE | - |
| CSF Aβ42/Aβ40 ratio | More accurate than Aβ42 alone | <0.05-0.08 suggests AD (assay-dependent) | - | ROUTINE | ROUTINE | - |
| 14-3-3 protein | Creutzfeldt-Jakob disease | Positive in CJD (not specific) | - | ROUTINE | ROUTINE | - |
| RT-QuIC | Prion disease confirmation | Positive indicates CJD | - | ROUTINE | ROUTINE | - |
| Autoimmune encephalitis panel | Autoimmune dementia | Negative | - | EXT | EXT | - |
| VDRL | Neurosyphilis | Nonreactive | - | ROUTINE | ROUTINE | - |

**Special Handling:** CSF biomarkers require specialized handling; send to reference lab; freeze within 1 hour
**Contraindications:** Coagulopathy (INR >1.5, platelets <50k); posterior fossa mass; skin infection at site

---

## 3. TREATMENT

### 3A. Acute/Emergent

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| Treat reversible causes | Various | Identified metabolic/infectious etiology | Per cause :: Various :: :: Correct hyponatremia, treat UTI, replace B12, treat hypothyroidism | Depends on intervention | Cognitive reassessment after treatment | STAT | STAT | ROUTINE | - |
| Thiamine (if nutritional risk) | IV/PO | Suspected Wernicke's; alcoholism; malnutrition | 500 mg IV TID x 3 days; 100 mg PO daily :: IV/PO :: :: 500 mg IV TID x 3 days if Wernicke suspected; then 100 mg PO daily | None | Clinical improvement | STAT | STAT | ROUTINE | - |
| Vitamin B12 | IM/PO | B12 deficiency | 1000 mcg IM daily x 7 days; 1000 mcg IM weekly x 4; 1000-2000 mcg PO daily :: IM/PO :: :: 1000 mcg IM daily x 7d, then weekly x 4wk, then monthly; or high-dose oral 1000-2000 mcg daily | None | B12 level, MMA; neuro improvement over months | - | ROUTINE | ROUTINE | - |

### 3B. Symptomatic Treatments (Behavioral)

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| Citalopram | PO | Depression; agitation in dementia | 10 mg daily; 20 mg daily :: PO :: :: Start 10 mg daily; max 20 mg in elderly (QT risk) | QT prolongation; concurrent QT-prolonging drugs | QTc (especially >20 mg) | - | ROUTINE | ROUTINE | - |
| Sertraline | PO | Depression; anxiety in dementia | 25 mg daily; 50 mg daily; 100 mg daily :: PO :: :: Start 25 mg daily; titrate by 25 mg q1-2wk; typical 50-100 mg | MAOIs | GI upset initially | - | ROUTINE | ROUTINE | - |
| Mirtazapine | PO | Depression with poor appetite and insomnia | 7.5 mg qHS; 15 mg qHS; 30 mg qHS :: PO :: :: Start 7.5-15 mg qHS; may increase to 30 mg qHS | MAOIs | Weight gain, sedation | - | ROUTINE | ROUTINE | - |
| Trazodone | PO | Insomnia; sundowning; agitation | 25 mg qHS; 50 mg qHS; 100 mg qHS :: PO :: :: Start 25-50 mg qHS; titrate by 25-50 mg; typical 50-150 mg qHS | Concurrent MAOIs; QT prolongation | Orthostatic hypotension, priapism (rare) | - | ROUTINE | ROUTINE | - |
| Quetiapine | PO | Severe agitation/psychosis when non-pharmacologic fails | 12.5 mg qHS; 25 mg BID; 50 mg BID :: PO :: :: Start 12.5-25 mg qHS; titrate slowly; keep dose as low as possible | Black box: increased mortality in dementia | Metabolic effects, sedation, QTc | - | EXT | ROUTINE | - |
| Risperidone | PO | Severe aggression/psychosis (short-term use only) | 0.25 mg BID; 0.5 mg BID :: PO :: :: Start 0.25 mg BID; max 1 mg BID; short-term use only | Black box: increased mortality in dementia | EPS, metabolic, stroke risk | - | EXT | ROUTINE | - |
| Haloperidol | IM/IV/PO | Acute severe agitation in delirium (not chronic) | 0.5 mg IM; 1 mg IM; 2 mg IM :: IM/IV/PO :: :: 0.5-2 mg IM/IV q4-6h PRN; short-term only; avoid chronic use | QT prolongation; Parkinson's; DLB | QTc, EPS | STAT | EXT | - | - |
| Melatonin | PO | Sleep disturbance; sundowning | 3 mg qHS; 6 mg qHS; 9 mg qHS :: PO :: :: Start 3 mg qHS; may increase to 9 mg; give 30 min before bed | None | Daytime sedation | - | ROUTINE | ROUTINE | - |

### 3C. Cognitive Enhancers

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| Donepezil | PO | Mild-moderate AD; vascular dementia; DLB | 5 mg qHS; 10 mg qHS; 23 mg daily :: PO :: :: Start 5 mg qHS x 4-6 weeks; increase to 10 mg qHS; 23 mg for moderate-severe | Sick sinus syndrome; GI bleeding; COPD exacerbation | Bradycardia, GI symptoms, vivid dreams | - | ROUTINE | ROUTINE | - |
| Rivastigmine oral | PO | Mild-moderate AD; Parkinson's dementia; DLB | 1.5 mg BID; 3 mg BID; 4.5 mg BID; 6 mg BID :: PO :: :: Start 1.5 mg BID; increase by 1.5 mg BID q2wk; target 6 mg BID | Same as donepezil; severe hepatic impairment | GI symptoms, weight loss | - | ROUTINE | ROUTINE | - |
| Rivastigmine patch | TD | Mild-moderate AD; better GI tolerability | 4.6 mg/24hr; 9.5 mg/24hr; 13.3 mg/24hr :: TD :: :: Start 4.6 mg/24hr patch; increase q4wk; target 9.5-13.3 mg/24hr | Same as oral | Skin irritation, GI symptoms | - | ROUTINE | ROUTINE | - |
| Galantamine | PO | Mild-moderate AD | 4 mg BID; 8 mg BID; 12 mg BID :: PO :: :: Start 4 mg BID x 4wk; increase to 8 mg BID x 4wk; target 8-12 mg BID | Same as donepezil; severe renal/hepatic | GI symptoms, bradycardia | - | ROUTINE | ROUTINE | - |
| Galantamine ER | PO | Once daily option | 8 mg daily; 16 mg daily; 24 mg daily :: PO :: :: Start 8 mg daily x 4wk; increase q4wk; target 16-24 mg daily | Same as IR | Same as IR | - | ROUTINE | ROUTINE | - |
| Memantine | PO | Moderate-severe AD; add to cholinesterase inhibitor | 5 mg daily; 5 mg BID; 10 mg BID :: PO :: :: Start 5 mg daily; increase by 5 mg/wk; target 10 mg BID | Severe renal impairment (dose adjust CrCl <30) | Confusion, dizziness, constipation | - | ROUTINE | ROUTINE | - |
| Memantine XR | PO | Once daily option | 7 mg daily; 14 mg daily; 21 mg daily; 28 mg daily :: PO :: :: Start 7 mg daily; increase by 7 mg/wk; target 28 mg daily | Same as IR | Same as IR | - | ROUTINE | ROUTINE | - |
| Memantine + Donepezil (Namzaric) | PO | Moderate-severe AD on both medications | 28/10 mg daily :: PO :: :: 28 mg memantine XR + 10 mg donepezil; take qHS | Same as individual drugs | Same as individual drugs | - | - | ROUTINE | - |

### 3D. Disease-Modifying Therapies (Anti-Amyloid)

| Treatment | Route | Indication | Dosing | Pre-Treatment Requirements | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|---------------------------|-------------------|------------|:--:|:----:|:---:|:---:|
| Lecanemab (Leqembi) | IV | Early AD with confirmed amyloid pathology (MCI or mild dementia) | 10 mg/kg IV q2wk :: IV :: :: 10 mg/kg IV every 2 weeks; infuse over 1 hour | Amyloid PET or CSF confirming amyloid; MRI baseline; APOE genotyping recommended | ARIA risk with anticoagulation; >4 microbleeds on MRI; recent stroke/TIA | MRI at baseline, weeks 14, 52, 78; monitor for ARIA-E/H | - | - | ROUTINE | - |
| Donanemab (Kisunla) | IV | Early AD with confirmed amyloid and tau pathology | 700 mg IV q4wk x 3; 1400 mg IV q4wk :: IV :: :: 700 mg q4wk x 3 doses, then 1400 mg q4wk until amyloid cleared | Amyloid PET positive; tau PET intermediate/high | Similar to lecanemab; higher ARIA risk with APOE4 homozygotes | MRI at baseline, weeks 16, 24, 52, 76; ARIA monitoring | - | - | EXT | - |
| Aducanumab (Aduhelm) | IV | Early AD with confirmed amyloid (limited use) | Titration to 10 mg/kg IV q4wk :: IV :: :: Slow titration: 1→3→6→10 mg/kg monthly | Same as lecanemab | Same as lecanemab; limited clinical adoption | MRI for ARIA monitoring | - | - | EXT | - |

**ARIA Monitoring Notes:**
- ARIA-E (edema): Usually asymptomatic; may cause headache, confusion
- ARIA-H (hemorrhage): Microbleeds, superficial siderosis
- Hold infusion for symptomatic ARIA; resume after resolution per protocol
- APOE4 homozygotes have higher ARIA risk; requires informed consent discussion

---

## 4. OTHER RECOMMENDATIONS

### 4A. Referrals & Consults

| Recommendation | ED | HOSP | OPD | ICU |
|----------------|:--:|:----:|:---:|:---:|
| Neurology/Cognitive neurology for diagnosis confirmation, subtype classification, and treatment planning | - | ROUTINE | ROUTINE | - |
| Neuropsychology for comprehensive cognitive testing to establish baseline and guide diagnosis | - | - | ROUTINE | - |
| Geriatric psychiatry for behavioral symptoms, medication management, and capacity evaluation | - | ROUTINE | ROUTINE | - |
| Occupational therapy for ADL assessment, cognitive strategies, and home safety evaluation | - | ROUTINE | ROUTINE | - |
| Speech therapy for communication strategies and swallowing evaluation if dysphagia present | - | ROUTINE | ROUTINE | - |
| Social work for caregiver support, community resources, and long-term care planning | - | ROUTINE | ROUTINE | - |
| Palliative care for advanced dementia symptom management and goals of care discussions | - | ROUTINE | ROUTINE | - |
| Legal/Elder law attorney for advance directives, healthcare proxy, and financial planning while patient has capacity | - | - | ROUTINE | - |
| Genetics counseling if familial/early-onset AD for family members | - | - | ROUTINE | - |

### 4B. Patient Instructions

| Recommendation | ED | HOSP | OPD |
|----------------|:--:|:----:|:---:|
| Return immediately if sudden confusion worsens which may indicate stroke, infection, or medication effect | STAT | STAT | ROUTINE |
| Complete advance directives while patient has capacity to document wishes for future care | - | ROUTINE | ROUTINE |
| Establish healthcare proxy/power of attorney for future decision-making | - | ROUTINE | ROUTINE |
| Do not drive if cognitive impairment affects judgment or reaction time (formal driving evaluation may be needed) | - | ROUTINE | ROUTINE |
| Take all medications as prescribed and use pill organizers or reminders to ensure adherence | - | ROUTINE | ROUTINE |
| Keep a consistent daily routine which helps with orientation and reduces confusion | - | ROUTINE | ROUTINE |
| Engage in mentally stimulating activities (reading, puzzles, social interaction) to support cognitive reserve | - | ROUTINE | ROUTINE |

### 4C. Lifestyle & Prevention

| Recommendation | ED | HOSP | OPD |
|----------------|:--:|:----:|:---:|
| Regular physical exercise (150 min/week moderate aerobic) may slow cognitive decline | - | ROUTINE | ROUTINE |
| Mediterranean or MIND diet emphasizing vegetables, berries, fish, nuts, and olive oil | - | ROUTINE | ROUTINE |
| Adequate sleep (7-8 hours) and treat sleep disorders (sleep apnea assessment) | - | ROUTINE | ROUTINE |
| Social engagement and cognitive stimulation through activities, hobbies, and relationships | - | ROUTINE | ROUTINE |
| Cardiovascular risk factor control (BP <130/80, diabetes control, cholesterol management) reduces vascular contribution | - | ROUTINE | ROUTINE |
| Hearing loss correction with hearing aids as untreated hearing loss is modifiable dementia risk factor | - | - | ROUTINE |
| Limit alcohol to ≤1 drink daily as excess alcohol accelerates cognitive decline | - | ROUTINE | ROUTINE |
| Fall prevention with home modifications as dementia increases fall and injury risk | - | ROUTINE | ROUTINE |

---

## SECTION B: REFERENCE

---

## 5. DIFFERENTIAL DIAGNOSIS

| Alternative Diagnosis | Key Distinguishing Features | Tests to Differentiate |
|-----------------------|----------------------------|------------------------|
| Delirium | Acute onset; fluctuating attention; identifiable cause (infection, medication, metabolic) | Resolve cause; reassess cognition when clear |
| Depression (pseudodementia) | Prominent mood symptoms; often aware of deficits; improves with antidepressants | GDS, PHQ-9; trial of antidepressant |
| Alzheimer's disease | Insidious onset; short-term memory most affected; language and visuospatial later | MRI hippocampal atrophy; amyloid/tau PET or CSF biomarkers |
| Vascular dementia | Stepwise decline; focal findings; executive dysfunction; vascular risk factors | MRI with significant white matter disease, strategic infarcts |
| Dementia with Lewy bodies | Visual hallucinations; parkinsonism; REM sleep behavior disorder; fluctuating cognition | DaTscan; clinical criteria |
| Frontotemporal dementia (behavioral) | Personality change; disinhibition; apathy; hyperorality; age <65 often | FDG-PET frontal hypometabolism; genetics |
| Primary progressive aphasia | Language predominates; word-finding, grammar, or comprehension primarily affected | Neuropsychological testing; FDG-PET language areas |
| Creutzfeldt-Jakob disease | Rapid progression (weeks-months); myoclonus; periodic sharp waves on EEG | EEG, MRI DWI cortical ribboning, CSF RT-QuIC |
| Normal pressure hydrocephalus | Gait disturbance prominent; urinary incontinence; dementia triad | MRI ventriculomegaly; LP with gait improvement test |
| Autoimmune encephalitis | Subacute onset; seizures; psychiatric features; often younger | Autoantibody panel (serum/CSF); MRI |

---

## 6. MONITORING PARAMETERS

| Parameter | Frequency | Target/Threshold | Action if Abnormal | ED | HOSP | OPD | ICU |
|-----------|-----------|------------------|-------------------|:--:|:----:|:---:|:---:|
| MMSE or MoCA | Every 6-12 months | Establish baseline; track trajectory | Adjust treatment; reassess diagnosis if unexpected decline | - | ROUTINE | ROUTINE | - |
| ADL/IADL function (FAQ, DAD) | Every 6-12 months | Document functional status for staging | Increase support services; OT referral | - | ROUTINE | ROUTINE | - |
| Behavioral symptoms (NPI) | Each visit | Identify and track BPSD | Behavioral interventions; consider medications | - | ROUTINE | ROUTINE | - |
| Weight | Each visit | Stable weight | Nutritional assessment; speech therapy for swallowing | - | ROUTINE | ROUTINE | - |
| Caregiver burden (Zarit scale) | Every 6-12 months | Early identification of burnout | Support resources; respite care; social work | - | - | ROUTINE | - |
| MRI (ARIA monitoring if on anti-amyloid) | Per protocol | No ARIA-E or ARIA-H | Hold infusion; follow protocol for resumption | - | - | ROUTINE | - |
| ECG (if on donepezil or citalopram) | Baseline; if dose increased | Normal QTc | Reduce dose or switch agent | - | ROUTINE | ROUTINE | - |
| Metabolic panel | Annually | Normal | Adjust medications | - | ROUTINE | ROUTINE | - |

---

## 7. DISPOSITION CRITERIA

| Disposition | Criteria |
|-------------|----------|
| Discharge home | Reversible causes treated; safe environment; caregiver support; follow-up arranged |
| Admit to floor | Acute delirium requiring workup; behavioral crisis unsafe for home; aspiration pneumonia |
| Admit to psychiatry | Severe behavioral disturbance requiring specialized psychiatric management |
| Outpatient follow-up | Neurology/geriatrics 1-3 months after diagnosis; then every 6-12 months |
| Long-term care | Progressive decline; caregiver unable to manage; safety concerns; 24-hour supervision needed |

---

## 8. EVIDENCE & REFERENCES

| Recommendation | Evidence Level | Source |
|----------------|----------------|--------|
| Cholinesterase inhibitors for mild-moderate AD | Class I, Level A | [Birks J. Cochrane 2006](https://pubmed.ncbi.nlm.nih.gov/16437532/) |
| Memantine for moderate-severe AD | Class I, Level A | [Reisberg et al. NEJM 2003](https://pubmed.ncbi.nlm.nih.gov/12672860/) |
| Combination therapy (ChEI + memantine) | Class I, Level A | [Tariot et al. JAMA 2004](https://pubmed.ncbi.nlm.nih.gov/14970063/) |
| Lecanemab slows cognitive decline in early AD | Class I, Level A | [van Dyck et al. NEJM 2023 (Clarity AD)](https://pubmed.ncbi.nlm.nih.gov/36449413/) |
| Donanemab slows cognitive decline | Class I, Level A | [Sims et al. JAMA 2023 (TRAILBLAZER-ALZ 2)](https://pubmed.ncbi.nlm.nih.gov/37459141/) |
| CSF biomarkers accurate for AD diagnosis | Class I, Level A | [Hansson et al. Lancet Neurol 2018](https://pubmed.ncbi.nlm.nih.gov/30244989/) |
| Mediterranean diet associated with lower dementia risk | Class II, Level B | [Scarmeas et al. Ann Neurol 2006](https://pubmed.ncbi.nlm.nih.gov/16832238/) |
| Physical exercise may slow cognitive decline | Class II, Level B | [Livingston et al. Lancet 2020 (Lancet Commission)](https://pubmed.ncbi.nlm.nih.gov/32738937/) |
| Avoid antipsychotics long-term (mortality risk) | Class I, Level A | [Schneider et al. JAMA 2005](https://pubmed.ncbi.nlm.nih.gov/16219884/) |
| B12 supplementation reverses deficiency-related cognitive impairment | Class II, Level B | [Smith et al. PLoS One 2010](https://pubmed.ncbi.nlm.nih.gov/20838622/) |

---

## CHANGE LOG

**v1.0 (January 27, 2026)**
- Initial template creation
- Comprehensive workup for reversible causes
- Includes new anti-amyloid therapies (lecanemab, donanemab)
- CSF biomarkers section included
- Structured dosing format for order sentence generation
